Role of Additional Novel Therapies in Myeloproliferative Neoplasms

Warren Fiskus; Siddhartha Ganguly; Suman Kambhampati; Kapil N. Bhalla

doi:10.1016/j.hoc.2012.07.001

Role of Additional Novel Therapies in Myeloproliferative Neoplasms

Warren Fiskus, Siddhartha Ganguly, Suman Kambhampati, Kapil N. Bhalla

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The recent approval of ruxolitinib (INCB018424) for myelofibrosis and the preclinical/clinical development of several additional janus kinase (JAK)-targeted agents have ushered in an era of novel therapies for advanced myeloproliferative neoplasms (MPN), which are associated with constitutive activation of the JAK-signal transducer and activation of transcription (STAT) signaling pathway. Collectively, these novel therapeutic approaches could rapidly broaden the spectrum of available therapies, with potential for improved clinical outcome for patients with advanced MPN. This review covers the recent developments in the testing of novel therapeutic agents other than JAK inhibitors that target signaling pathways in addition to JAK/STAT, or target the deregulated epigenetic mechanisms in MPN.

Original language	English (US)
Pages (from-to)	959-980
Number of pages	22
Journal	Hematology/Oncology Clinics of North America
Volume	26
Issue number	5
DOIs	https://doi.org/10.1016/j.hoc.2012.07.001
State	Published - Oct 2012

Keywords

HDAC inhibitor
Hsp90 inhibitors
JAK2-V617F
MEK inhibitor
Myeloproliferative neoplasms
PI3K/AKT inhibitor

ASJC Scopus subject areas

Oncology
Hematology

Access to Document

10.1016/j.hoc.2012.07.001

Cite this

@article{7b93476a802f43ea8ec7446a2d2f1d25,

title = "Role of Additional Novel Therapies in Myeloproliferative Neoplasms",

abstract = "The recent approval of ruxolitinib (INCB018424) for myelofibrosis and the preclinical/clinical development of several additional janus kinase (JAK)-targeted agents have ushered in an era of novel therapies for advanced myeloproliferative neoplasms (MPN), which are associated with constitutive activation of the JAK-signal transducer and activation of transcription (STAT) signaling pathway. Collectively, these novel therapeutic approaches could rapidly broaden the spectrum of available therapies, with potential for improved clinical outcome for patients with advanced MPN. This review covers the recent developments in the testing of novel therapeutic agents other than JAK inhibitors that target signaling pathways in addition to JAK/STAT, or target the deregulated epigenetic mechanisms in MPN.",

keywords = "HDAC inhibitor, Hsp90 inhibitors, JAK2-V617F, MEK inhibitor, Myeloproliferative neoplasms, PI3K/AKT inhibitor",

author = "Warren Fiskus and Siddhartha Ganguly and Suman Kambhampati and Bhalla, {Kapil N.}",

year = "2012",

month = oct,

doi = "10.1016/j.hoc.2012.07.001",

language = "English (US)",

volume = "26",

pages = "959--980",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - Role of Additional Novel Therapies in Myeloproliferative Neoplasms

AU - Fiskus, Warren

AU - Ganguly, Siddhartha

AU - Kambhampati, Suman

AU - Bhalla, Kapil N.

PY - 2012/10

Y1 - 2012/10

N2 - The recent approval of ruxolitinib (INCB018424) for myelofibrosis and the preclinical/clinical development of several additional janus kinase (JAK)-targeted agents have ushered in an era of novel therapies for advanced myeloproliferative neoplasms (MPN), which are associated with constitutive activation of the JAK-signal transducer and activation of transcription (STAT) signaling pathway. Collectively, these novel therapeutic approaches could rapidly broaden the spectrum of available therapies, with potential for improved clinical outcome for patients with advanced MPN. This review covers the recent developments in the testing of novel therapeutic agents other than JAK inhibitors that target signaling pathways in addition to JAK/STAT, or target the deregulated epigenetic mechanisms in MPN.

AB - The recent approval of ruxolitinib (INCB018424) for myelofibrosis and the preclinical/clinical development of several additional janus kinase (JAK)-targeted agents have ushered in an era of novel therapies for advanced myeloproliferative neoplasms (MPN), which are associated with constitutive activation of the JAK-signal transducer and activation of transcription (STAT) signaling pathway. Collectively, these novel therapeutic approaches could rapidly broaden the spectrum of available therapies, with potential for improved clinical outcome for patients with advanced MPN. This review covers the recent developments in the testing of novel therapeutic agents other than JAK inhibitors that target signaling pathways in addition to JAK/STAT, or target the deregulated epigenetic mechanisms in MPN.

KW - HDAC inhibitor

KW - Hsp90 inhibitors

KW - JAK2-V617F

KW - MEK inhibitor

KW - Myeloproliferative neoplasms

KW - PI3K/AKT inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84866633871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866633871&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2012.07.001

DO - 10.1016/j.hoc.2012.07.001

M3 - Review article

C2 - 23009932

AN - SCOPUS:84866633871

VL - 26

SP - 959

EP - 980

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 5

ER -

Role of Additional Novel Therapies in Myeloproliferative Neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this